MOF Drug Delivery Landscape 2026 — PatSnap Eureka
Metal-Organic Framework Drug Delivery: 2026 Innovation Landscape
MOFs offer ultrahigh surface areas of 1,000–7,000 m²/g and stimulus-responsive release that surpasses lipid nanoparticles, polymeric micelles, and mesoporous silica — transforming oncology, antimicrobial, and theranostic drug delivery. Explore the full patent and literature landscape with PatSnap Eureka.
What Makes MOFs a Transformative Drug Delivery Platform?
Metal-organic frameworks for drug delivery are defined by the coordination of metal ions or clusters — including Fe, Zr, Al, Cu, and Zn — with polyfunctional organic ligands to form three-dimensional, highly porous crystalline networks. This architecture delivers a combination of record-level porosity and the ability to engineer both the pore chemistry and external surface for stimulus-responsive, targeted release that no conventional nanocarrier can match.
Drug loading strategies span pore encapsulation (physical entrapment), surface adsorption, covalent binding to linker groups, and use of bioactive ligands or metal nodes as intrinsic therapeutic elements. Compared to lipid nanoparticles, polymeric micelles, and mesoporous silica, MOFs offer superior loading capacity — with surface areas of 1,000–7,000 m²/g and pore volumes of 1.04–4.40 cm³/g documented in the literature.
The field has matured from foundational proof-of-concept studies into a sophisticated discipline encompassing targeted oncology, antimicrobial, and multi-modal theranostic applications. Research from institutions including the PatSnap life sciences intelligence platform, Shanghai Institute of Materia Medica (Chinese Academy of Sciences), and University of Glasgow has established comprehensive classification of MOF-based drug delivery systems by metal and ligand type.
The World Intellectual Property Organization (WIPO) tracks growing international patent activity in nanomaterial-based drug delivery, consistent with the academic output acceleration observed in this dataset from 2016 onward.
Four Core Technology Approaches in MOF Drug Delivery
The dataset reveals four distinct research clusters, from passive encapsulation through to multi-agent composite nanoplatforms, each representing a different stage of technical maturity.
Passive Encapsulation in Porous MOF Architectures
The most foundational approach exploits the extraordinarily high surface area and defined micropore structure of MOFs to physically entrap drug molecules without covalent modification. MIL-53(Al) via microwave-assisted synthesis achieves drug loading reaching 34% by particle weight, significantly exceeding other solid nanoparticle systems. Nano-MIL-100(Fe) demonstrates sustained release of tetracycline-class antibiotics confirmed by BET, XRD, and FTIR characterization.
Loading up to 34% by weightStimulus-Responsive (Smart) MOF Delivery Systems
MOFs engineered to release cargo in response to tumor microenvironment cues (pH, redox, reactive oxygen species) or external stimuli (light, magnetic field, temperature). Nine distinct stimuli have been catalogued for anticancer drug delivery. Fe-MOF/tannic acid nanocomplexes release DOX and Fe²⁺ under acidic tumor microenvironment, enabling Fenton-reaction-based chemodynamic therapy (CDT) concurrent with chemotherapy — a modality unavailable to lipid nanoparticles or polymeric systems.
9 distinct stimuli documentedSurface-Functionalized and Targeted MOF Nanocarriers
Covalent and non-covalent surface modification of MOFs with targeting ligands — including folic acid, aptamers, antibodies, and DNA nanostructures — achieves active tumor targeting and reduced off-target toxicity. MIL-101(Fe)@FU@FA (~500 nm) with folic acid conjugated to 5-FU-loaded MIL-101(Fe)-NH₂ demonstrates superior inhibition of SMMC-7721 hepatocellular carcinoma cells. UiO-66 NMOFs gated by aptamer-functionalized DNA tetrahedra enable dual-modality chemo + photodynamic therapy.
Folate receptor-targeted deliveryMOF Composites and Multi-Agent Delivery Platforms
MOF-based composite systems — core-shell structures, MOF-polymer, MOF-graphene oxide, MOF-polysilsesquioxane — overcome standalone MOF limitations including poor aqueous stability, limited biocompatibility, and single-drug payload restriction. A CMC/MOF-5/GO ternary nanocomposite integrates MOF porosity, graphene oxide surface area, and cellulose biocompatibility. Multi-agent MOF platforms simultaneously deliver a biologically active gas, an antibiotic drug molecule, and an active metal ion, each released at different rates, with potent antibacterial activity confirmed against multiple bacterial strains.
Multi-agent simultaneous releaseMOF Drug Delivery: Key Metrics from the Innovation Dataset
All data derived from patent and literature records retrieved via PatSnap Eureka. Figures reflect the retrieved dataset only and represent innovation signals, not comprehensive industry totals.
Drug Loading Efficiency: MOF Families vs. Conventional Nanocarriers
MIL-53(Al) achieves 34% loading by particle weight — significantly exceeding lipid nanoparticles and mesoporous silica. UiO and ZIF series also outperform conventional systems.
MOF Drug Delivery Application Domain Distribution
Oncology and anti-tumor therapy is the dominant application domain in the dataset. Anti-infective and anti-inflammatory applications form a significant secondary tier, with theranostics emerging.
MOF Drug Delivery Applications Across Disease Areas
From oncology to anti-infective to theranostics — the application breadth of MOF platforms is expanding rapidly, with each domain presenting distinct IP and R&D opportunities.
| Application Domain | Representative MOF Systems | Key Payloads | Maturity Signal | Lead Institutions in Dataset |
|---|---|---|---|---|
| Oncology / Anti-Tumor | MIL-101(Fe), UiO-66, ZIF, Fe-MOF/TA, HKUST-1 | Doxorubicin (DOX), 5-Fluorouracil (5-FU) | Dominant — most records | Beijing Univ. of Chinese Medicine; Guangxi Univ. Medical College; Naval Medical Univ. Shanghai |
| Anti-Infective / Antimicrobial | Nano-MIL-100(Fe), MOF-5, CMC/MOF-5/GO composite | Tetracycline, Doxycycline, Active metal ions, Biologically active gas | Active — sustained release confirmed | University of Tehran; Jagiellonian University; University of Tabriz |
| Anti-Inflammatory | Ca-MOF, Fe-MIL series, Multi-MIL-100(Fe) | Flurbiprofen (NSAID), Aceclofenac (NSAID) | Emerging — aqueous solubility driver | Pharmaceutics Dept. School of Pharmacy (2017, 2018) |
Identify IP White Space Across All MOF Application Domains
PatSnap Eureka maps patent claims by application domain, helping R&D and IP teams find unprotected formulation space.
Four Forward-Looking MOF Innovation Vectors
Based on publications from 2021–2023 in the retrieved dataset, four directions signal where the field is heading — and where differentiated IP can be built.
Biomacromolecule Delivery via MOFs
The shift from small-molecule drug carriers to nucleic acid (siRNA, aptamer, DNA) and protein delivery is explicitly flagged as a frontier. Aptamer-gated MOF release from UiO-66 NMOFs provides proof-of-concept for biomarker-responsive cargo release and dual-modality chemo + photodynamic therapy. This is identified as the next development stage after small-molecule loading by Naval Medical University Shanghai (2022).
Chemodynamic Therapy (CDT) Integration
Fe-based MOFs are being engineered specifically to exploit Fenton chemistry within the acidic tumor microenvironment, generating hydroxyl radicals in situ. Fe-MOF/tannic acid nanocomplex (MTD) releases DOX and Fe²⁺ under acidic conditions, enabling CDT concurrent with chemotherapy — a therapeutic modality with no equivalent in earlier-era nanocarrier platforms. Demonstrated by Guangxi University Medical College (2022).
China Dominates Applied Research; Western Institutions Lead Mechanistic Understanding
Innovation geography for MOF drug delivery is markedly concentrated in China and the United Kingdom, with meaningful contributions from Iran, Russia, Poland, Israel, Taiwan, and the United Arab Emirates. China is the most represented jurisdiction in the dataset by institution count, with the breadth and recency (2020–2022) of Chinese contributions signalling sustained state-level investment.
Contributing Chinese institutions include Guangxi University Medical College, Bengbu Medical College, Beijing University of Chinese Medicine, Naval Medical University Shanghai, National Tsing Hua University (Taiwan), Heilongjiang University of TCM, Guizhou University, and Shanghai Institute of Materia Medica (Chinese Academy of Sciences). The PatSnap life sciences intelligence platform enables monitoring of Chinese academic institution filings in real time.
The United Kingdom contributes high-impact mechanistic studies, including the University of Glasgow's real-time intracellular release study and University of Cambridge's review on MOF endocytosis mechanisms. The European Patent Office (EPO) records growing European academic MOF filings consistent with this mechanistic research leadership.
No dominant single commercial assignee is identifiable in the dataset. Innovation is distributed across academic institutions with no large pharmaceutical or materials company emerging as a clear filing leader. This is consistent with the pre-commercial stage of MOF drug delivery as a technology platform — and represents a significant IP white space opportunity for organisations with patent landscape analytics capabilities.
Patent-format records in the dataset (US, EP jurisdictions) address adjacent drug delivery technologies rather than MOF-specific claims, suggesting that the MOF drug delivery patent estate may be concentrated in academic institution filings. The USPTO and EP patent databases should be monitored alongside academic literature for a complete freedom-to-operate picture.
MOF Drug Delivery Maturity: From Foundational to Translational
Publication dates in the retrieved dataset span 2010 to 2025, with a clear acceleration in MOF-specific drug delivery research from 2016 onward across four distinct innovation eras.
MOF Drug Delivery Innovation Timeline: Four Eras (2010–2025)
Each era is characterised by a distinct research focus — from structural concepts through mechanistic development, scale-up and targeting, to integration and clinical translation challenges.
Metal-Organic Framework Drug Delivery — Key Questions Answered
Metal-organic frameworks (MOFs) are crystalline, porous hybrid materials assembled from metal ions or clusters and organic ligands. They are used for drug delivery because they offer ultrahigh surface areas (1,000–7,000 m²/g), tunable pore sizes, and stimulus-responsive release capabilities that surpass conventional nanocarriers such as lipid nanoparticles, polymeric micelles, and mesoporous silica.
The most prominently referenced MOF families include the MIL series (MIL-53(Al), MIL-100(Fe), MIL-101(Fe/Cr)), the UiO series (UiO-66 and UiO-66-NH₂), the ZIF series (zeolitic imidazolate frameworks with pH-responsive degradation), HKUST-1 (copper-based, studied for chemotherapeutic encapsulation), and MOF-5 (zinc-based, investigated in antibacterial drug composites).
Drug loading of chemotherapeutic and diagnostic molecules reaching 34% by particle weight has been reported using microwave-assisted synthesis of MIL-53(Al), significantly exceeding other solid nanoparticle systems. Pore volumes of 1.04–4.40 cm³/g have also been documented alongside surface areas of 1,000–7,000 m²/g.
MOF-based stimuli-responsive systems have been engineered to respond to nine distinct stimuli: pH, magnetic field, ion concentration, temperature, pressure, light, humidity, redox potential, and multiple combined stimuli. These are deployed primarily for anticancer drug delivery targeting the tumor microenvironment.
Chemodynamic therapy (CDT) using MOFs involves engineering Fe-based MOFs to exploit Fenton chemistry within the acidic tumor microenvironment, generating hydroxyl radicals in situ. An Fe-MOF/tannic acid nanocomplex (MTD) that releases DOX and Fe²⁺ under acidic tumor microenvironment conditions, enabling Fenton-reaction-based CDT concurrent with chemotherapy, has been demonstrated.
Innovation geography for MOF drug delivery is markedly concentrated in China and the United Kingdom, with meaningful contributions from Iran, Russia, Poland, Israel, Taiwan, and the United Arab Emirates. China is the most represented jurisdiction by institution count, with the breadth and recency (2020–2022) of Chinese contributions signalling sustained state-level investment. No dominant single commercial assignee is identifiable; innovation is distributed across academic institutions.
Still have questions about MOF drug delivery IP? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About MOFsAccelerate Your MOF Drug Delivery R&D and IP Strategy
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D. Map MOF patent white space, track Chinese academic filings, and identify CDT and composite formulation opportunities — before competitors do.
References
- MIL-53 (Al) metal-organic frameworks as potential drug carriers — National Research Nuclear University MEPhI, Russia, 2021
- Applications of Metal-Organic Frameworks as Drug Delivery Systems — Coriolan Dragulescu Institute of Chemistry, Romania, 2022
- Multimetal organic frameworks as drug carriers: aceclofenac as a drug candidate — Pharmaceutics Department School of Pharmacy, 2018
- Metal-organic frameworks for advanced drug delivery — Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China, 2021
- Recent Advances in Metal–Organic-Framework-Based Nanocarriers for Controllable Drug Delivery and Release — Youjiang Medical University for Nationalities, China, 2022
- Drug delivery and controlled release from biocompatible metal–organic frameworks using mechanical amorphization — UK, 2016
- Metal Organic Frameworks as Drug Targeting Delivery Vehicles in the Treatment of Cancer — Beijing University of Chinese Medicine, China, 2020
- Multirate delivery of multiple therapeutic agents from metal-organic frameworks — Jagiellonian University, Poland, 2014
- Metal–Organic Framework‐Based Stimuli‐Responsive Systems for Drug Delivery — Xi'an Jiaotong University Health Science Center, China, 2018
- BioMOF-Based Anti-Cancer Drug Delivery Systems — United Arab Emirates University, UAE, 2023
- Metal–Organic Framework Nanocarriers for Drug Delivery in Biomedical Applications — Foundation for Applied Molecular Evolution, USA, 2020
- Identifying Differing Intracellular Cargo Release Mechanisms by Monitoring In Vitro Drug Delivery from MOFs in Real Time — University of Glasgow, UK, 2020
- Doxorubicin-Loaded Metal-Organic Framework Nanoparticles as Acid-Activatable Hydroxyl Radical Nanogenerators for Enhanced Chemo/Chemodynamic Synergistic Therapy — Guangxi University Medical College, China, 2022
- Application of Metal-Organic Framework Nano-MIL-100(Fe) for Sustainable Release of Doxycycline and Tetracycline — University of Tehran, Iran, 2017
- Metal organic frameworks as a drug delivery system for flurbiprofen — Pharmaceutics Department School of Pharmacy, 2017
- Strategy for chemotherapeutic delivery using a nanosized porous metal-organic framework with a central composite design — Heilongjiang University of Traditional Chinese Medicine, China, 2017
- Aptamer-modified DNA tetrahedra-gated metal–organic framework nanoparticle carriers for enhanced chemotherapy or photodynamic therapy — Hebrew University of Jerusalem, Israel, 2021
- A surface architectured metal–organic framework for targeting delivery: Suppresses cancer growth and metastasis — Bengbu Medical College, China, 2022
- Metal–Organic Frameworks as Intelligent Drug Nanocarriers for Cancer Therapy — Second Affiliated Hospital of Naval Medical University, Shanghai, China, 2022
- Advances in Functional Metal‐Organic Frameworks Based On‐Demand Drug Delivery Systems for Tumor Therapeutics — National Tsing Hua University, Taiwan, 2021
- Biomedical Applications of Metal−Organic Frameworks for Disease Diagnosis and Drug Delivery: A Review — American University of Sharjah, UAE, 2022
- World Intellectual Property Organization (WIPO) — International patent activity in nanomaterial-based drug delivery
- European Patent Office (EPO) — European academic MOF patent filings
- National Institutes of Health (NIH) — Lipid nanoparticle and nanocarrier drug delivery research
- United States Patent and Trademark Office (USPTO) — US patent records for drug delivery technologies
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This landscape is derived from a limited set of patent and literature records retrieved across targeted searches. It represents a snapshot of innovation signals within this dataset only and should not be interpreted as a comprehensive view of the full industry.
PatSnap Eureka searches patents and research to answer instantly.